$INM
InMed Pharmaceuticals Inc. Stock $inm

$inm Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024098445 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$1.265M	$901.9K
YoY Change		40.23%	181.14%
Cost Of Revenue		$771.2K	$787.7K
YoY Change		-2.09%	235.14%
Gross Profit		$493.4K	$21.24K
YoY Change		2222.82%	-104.33%
Gross Profit Margin		39.02%	2.36%
Selling, General & Admin		$1.422M	$1.300M
YoY Change		9.38%	-16.69%
% of Gross Profit		288.18%	6119.95%
Research & Development		$771.2K	$1.292M
YoY Change		-40.32%	-6.28%
% of Gross Profit		156.3%	6082.73%
Depreciation & Amortization		$54.58K	$54.83K
YoY Change		-0.46%	11.79%
% of Gross Profit		11.06%	258.13%
Operating Expenses		$2.228M	$2.694M
YoY Change		-17.29%	-9.84%
Operating Profit		-$1.735M	-$2.537M
YoY Change		-31.61%	-27.73%
Interest Expense		$76.40K	$90.00K
YoY Change		-15.11%	-471.9%
% of Operating Profit
Other Income/Expense, Net			$136.0K
YoY Change			106.79%
Pretax Income		-$1.678M	-$2.537M
YoY Change		-33.86%	-27.59%
Income Tax
% Of Pretax Income
Net Earnings		-$1.678M	-$2.500M
YoY Change		-32.89%	-28.78%
Net Earnings / Revenue		-132.68%	-277.2%
Basic Earnings Per Share		-$2.71	-$0.76
Diluted Earnings Per Share		-$2.71	-$0.76
COMMON SHARES
Basic Shares Outstanding	718.0K shares	13.34M shares	3.328M shares
Diluted Shares Outstanding		620.1K shares	3.328M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.626M	$6.780M
YoY Change	-17.02%	-27.82%
Cash & Equivalents	$5.583M	$6.738M
Short-Term Investments	$43.20K	$40.00K
Other Short-Term Assets	$148.9K	$220.0K
YoY Change	-32.33%	-38.32%
Inventory	$1.220M	$1.133M
Prepaid Expenses
Receivables	$284.7K	$165.9K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$7.280M	$8.295M
YoY Change	-12.24%	-28.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.343M	$615.1K
YoY Change	118.36%	-23.35%
Goodwill
YoY Change
Intangibles	$1.742M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$101.8K
YoY Change	-1.76%	-40.52%
Total Long-Term Assets	$3.185M	$2.622M
YoY Change	21.47%	-13.79%
TOTAL ASSETS
Total Short-Term Assets	$7.280M	$8.295M
Total Long-Term Assets	$3.185M	$2.622M
Total Assets	$10.47M	$10.92M
YoY Change	-4.14%	-25.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.000K	$380.0K
YoY Change	-99.47%	-65.34%
Accrued Expenses	$85.52K	$960.0K
YoY Change	-91.09%	-42.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.436M	$1.339M
YoY Change	7.22%	-59.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$633.8K	$0.00
YoY Change		-100.0%
Total Long-Term Liabilities	$633.8K	$0.00
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.436M	$1.339M
Total Long-Term Liabilities	$633.8K	$0.00
Total Liabilities	$2.070M	$1.339M
YoY Change	54.54%	-62.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.8M	-$103.9M
YoY Change	6.64%	7.15%
Common Stock	$119.0M	$113.4M
YoY Change	4.97%	56.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.395M	$9.578M
YoY Change
Total Liabilities & Shareholders Equity	$10.47M	$10.92M
YoY Change	-4.14%	-25.14%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$1.678M	-$2.500M
YoY Change	-32.89%	-28.78%
Depreciation, Depletion And Amortization	$54.58K	$54.83K
YoY Change	-0.46%	11.79%
Cash From Operating Activities	-$1.827M	-$2.174M
YoY Change	-15.98%	-3.61%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$838.2K
YoY Change
NET CHANGE
Cash From Operating Activities	-$1.827M	-$2.174M
Cash From Investing Activities
Cash From Financing Activities	$838.2K
Net Change In Cash	-$988.6K	-$2.174M
YoY Change	-54.53%	-168.51%
FREE CASH FLOW
Cash From Operating Activities	-$1.827M	-$2.174M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2024	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare
CY2024Q3	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2024Q3	dei	Document Type DocumentType	10-Q
CY2024Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q3	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q3	dei	Entity File Number EntityFileNumber	001-39685
CY2024Q3	dei	Entity Registrant Name EntityRegistrantName	INMED PHARMACEUTICALS INC.
CY2024Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2024Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1428279
CY2024Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	Suite 1445 - 885 W. Georgia Street
CY2024Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	Vancouver
CY2024Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	B.C
CY2024Q3	dei	Entity Address Country EntityAddressCountry	CA
CY2024Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V6C 3E8
CY2024Q3	dei	City Area Code CityAreaCode	(604)
CY2024Q3	dei	Local Phone Number LocalPhoneNumber	669-7207
CY2024Q3	dei	Security12b Title Security12bTitle	Common Shares, no par value
CY2024Q3	dei	Trading Symbol TradingSymbol	INM
CY2024Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q3	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q3	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	718032	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5583039	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6571610	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	43203	usd
CY2024Q2	us-gaap	Short Term Investments ShortTermInvestments	43064	usd
CY2024Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	66775	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	284695	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	352838	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	1220073	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1244324	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	148882	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	477749	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	7279892	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	8689585	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1343009	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1249999	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1742205	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1783198	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	100000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	100000	usd
CY2024Q3	us-gaap	Assets Assets	10465106	usd
CY2024Q2	us-gaap	Assets Assets	11822782	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1011619	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1654011	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	424260	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	317797	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1435879	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1971808	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	633783	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	644865	usd
CY2024Q3	us-gaap	Liabilities Liabilities	2069662	usd
CY2024Q2	us-gaap	Liabilities Liabilities	2616673	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	667013	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	667013	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	445948	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	445948	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	84198673	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	82784400	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	34821829	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35368899	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110753627	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109075759	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	8395444	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	9206109	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10465106	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11822782	usd
CY2024Q3	us-gaap	Revenues Revenues	1264638	usd
CY2023Q3	us-gaap	Revenues Revenues	901862	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	771225	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	880620	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	493413	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	21242	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	771180	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1292093	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1421926	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1298731	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54579	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54832	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	19310	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-48457	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	2228375	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2694113	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	57094	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	136043	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1677868	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2536828	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1677868	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2536828	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.71
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.71
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-15.24
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-15.24
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	620127	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	620127	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	166410	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	166410	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	9206109	usd
CY2024Q3	inm	Stock Issued During Period Value Issued For Private Placement StockIssuedDuringPeriodValueIssuedForPrivatePlacement	1030063	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	191824	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1677868	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	28964	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	8395444	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2536828	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	25191	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-9578090	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1677868	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2536828	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	54579	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	54832	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	28964	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	25191	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	90401	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94532	usd
CY2024Q3	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	519	usd
CY2023Q3	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	538	usd
CY2024Q3	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	5270	usd
CY2023Q3	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	2018	usd
CY2024Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	92930	usd
CY2024Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-24251	usd
CY2023Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-390329	usd
CY2024Q3	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-328867	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-283018	usd
CY2023Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3118	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-68143	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-94549	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-642392	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-562484	usd
CY2023Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-16171	usd
CY2024Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-106506	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-98709	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1826810	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2174213	usd
CY2024Q3	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	21324	usd
CY2023Q3	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	21317	usd
CY2024Q3	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	21324	usd
CY2023Q3	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	21317	usd
CY2024Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1030063	usd
CY2024Q3	inm	Private Placement Issuance Costs PrivatePlacementIssuanceCosts	191824	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	838239	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-988571	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2174213	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6571610	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8912517	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5583039	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6738304	usd
CY2024Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	187223	usd
CY2024Q3	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CORPORATE INFORMATION AND CONTINUING OPERATIONS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the <i>Business Corporations Act</i> of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s office and principal place of business is located at Suite 1445– 885 West Georgia Street, Vancouver, B.C., Canada, V6C 1B4. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 1.2pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Through September 30, 2024, the Company has funded its operations primarily with proceeds from the sale of the Company’s common shares, no par value per share (the “Common Shares”). The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of approximately $1.7 and $2.5 million for the three months ended September 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of approximately $110.8 million as of September 30, 2024. The Company expects to continue to generate operating losses for the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of the issuance date of these unaudited condensed consolidated financial statements, the Company expects its cash, cash equivalents and short-term investments of $5.6 million as of September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements through the end of the first quarter of calendar 2025, depending on the level and timing of realizing BayMedica revenues from the sale of bulk rare cannabinoids in the ‘health & wellness’ sector as well as the level and timing of Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In connection with the Company’s assessment of going concern considerations in accordance with Subtopic 205-40, management has determined that the Company’s liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern, which is considered to be for a period of one year from the issuance of these condensed consolidated financial statements. These unaudited condensed consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts of classification of liabilities that might result from the outcome of this uncertainty. Such adjustments could be material.</p>
CY2024Q3	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1981-05-19
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1700000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2500000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110800000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	5600000	usd
CY2024Q3	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Certain prior year amounts in the unaudited condensed consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year’s presentation. These reclassifications did not affect the prior period’s total assets, total liabilities, stockholders’ deficit, net loss or net cash used in operating activities. During the year ended June 30, 2024, the Company adopted ASU 2023-07 - Improvements to Reportable Segment Disclosures which has required prior periods to reflect the change in presentation. Refer to discussion on Recent Accounting Pronouncements below.</p>
CY2024Q3	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these unaudited condensed consolidated financial statements are the application of the going concern assumptions, determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, and the assumptions used in the determination of research & development accruals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Actual results could differ from those estimates.</p>
CY2024Q3	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	1964203	usd
CY2024Q2	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	1939482	usd
CY2024Q3	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) or Canadian Deposit Insurance Corporation insurable limits. The Company has not previously experienced any losses related to these balances. The uninsured cash balance as of September 30, 2024 was $1.6 million. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company’s customers are primarily concentrated in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of September 30, 2024, the Company had four customers with an accounts receivable balance representing 25%, 23%, 22%, and 20% of total accounts receivable. As of June 30, 2024, we had five customers with an accounts receivable balance representing 32%, 20%, 15%,15% and 14% of total accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For the three months ended September 30, 2024, the Company had four customers that accounted for 22%, 20%, 18%, and 15% of revenue. For the three months ended September 30, 2023, the Company had three customers that accounted for 34%, 20%, and 11% of revenue.</p>
CY2024Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1600000	usd
CY2024Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	92930	usd
CY2024Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	543326	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	180933	shares
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	274445	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	372695	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	18446	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	30817	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	927182	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	840812	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	1220073	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1244324	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2371193	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2605310	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1028184	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1355311	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1343009	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1249999	usd
CY2024Q3	us-gaap	Depreciation Depreciation	13586	usd
CY2023Q3	us-gaap	Depreciation Depreciation	13839	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	90401	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94532	usd
CY2024Q3	inm	Finite Lived Intellectual Property FiniteLivedIntellectualProperty	1736420	usd
CY2024Q2	inm	Finite Lived Intellectual Property FiniteLivedIntellectualProperty	1736420	usd
CY2024Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2024Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1185215	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1144222	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1742205	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1783198	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P18Y
CY2024Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
CY2024Q3	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P11Y
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40993	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40993	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	162746	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	162746	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	162746	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	162746	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	162746	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	928475	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1742205	usd
CY2024Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	448995	usd
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	626190	usd
CY2024Q3	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	238412	usd
CY2024Q2	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	242066	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	41004	usd
CY2024Q3	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	236691	usd
CY2024Q2	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	488278	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85521	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	256473	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1011619	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1654011	usd
CY2024Q3	inm	Proceed From Issuance Of Share Capital And Reserves ProceedFromIssuanceOfShareCapitalAndReserves	1000000	usd
CY2024Q3	us-gaap	Payments For Fees PaymentsForFees	192000	usd
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20	pure
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	35000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20	pure
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10804	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	163
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	22919	shares
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.4
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28964	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25191	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y3M18D
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	469668	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	453191	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	219261	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1142120	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	84077	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1058043	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	424260	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	633783	usd
CY2024Q3	us-gaap	Area Of Land AreaOfLand	2243	sqm
CY2024Q3	us-gaap	Payments For Rent PaymentsForRent	12296	usd
CY2024Q3	inm	Estimated Agreement Term EstimatedAgreementTerm	two-year
CY2024Q3	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.07	pure
CY2024Q3	inm	Corresponding Operating Lease Liability CorrespondingOperatingLeaseLiability	205201	usd
CY2023Q4	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	1295759	usd
CY2023Q4	us-gaap	Lessee Operating Lease Option To Terminate LesseeOperatingLeaseOptionToTerminate	three-year
CY2023Q4	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.0615	pure
CY2023Q4	inm	Corresponding Operating Lease Liability CorrespondingOperatingLeaseLiability	953935	usd
CY2024Q3	us-gaap	Revenues Revenues	1264638	usd
CY2023Q3	us-gaap	Revenues Revenues	901862	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	771225	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	880620	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	771180	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1292093	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1421926	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1298731	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54579	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54832	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	19310	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-48457	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	57094	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	136043	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1677868	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2536828	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5583039	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6738304	usd
CY2024Q3	us-gaap	Cost Direct Material CostDirectMaterial	422270	usd
CY2024Q3	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	43203	usd
CY2024Q2	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	43064	usd
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	700	shares
CY2023Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	300000	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2024Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets		usd
CY2024Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023Q3	inm	Private Placement Issuance Costs PrivatePlacementIssuanceCosts		usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2024Q3	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q3	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive		usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2024Q3	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001728328

Files In Submission

Name	View Source	Status
0001213900-24-098445-index-headers.html	Edgar Link	pending
0001213900-24-098445-index.html	Edgar Link	pending
0001213900-24-098445.txt	Edgar Link	pending
0001213900-24-098445-xbrl.zip	Edgar Link	pending
ea0219774-10q_inmed.htm	Edgar Link	pending
ea021977401ex31-1_inmed.htm	Edgar Link	pending
ea021977401ex31-2_inmed.htm	Edgar Link	pending
ea021977401ex32-1_inmed.htm	Edgar Link	pending
ea0219774-10q_inmed_htm.xml	Edgar Link	completed
ea021977401ex32-2_inmed.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
inm-20240930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
inm-20240930_cal.xml	Edgar Link	unprocessable
inm-20240930_def.xml	Edgar Link	unprocessable
inm-20240930_lab.xml	Edgar Link	unprocessable
inm-20240930_pre.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INM
InMed Pharmaceuticals Inc. Stock $inm

2024 Q4 Form 10-Q Financial Statement

#000121390024098445 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM InMed Pharmaceuticals Inc. Stock $inm

2024 Q4 Form 10-Q Financial Statement

#000121390024098445 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM
InMed Pharmaceuticals Inc. Stock $inm